Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 583 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GI Clear all
Terminated Phase 3 Interventional

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

NCT05171075
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Abelacimab, Dalteparin
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Evanston, Illinois • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform

NCT02436057
View directory record Official record
Conditions
Abdominal Pain, Deglutition Disorders, Fecal Incontinence, Nausea, Diarrhea, Constipation, Gastroesophageal Reflux
Interventions
AEGIS (Automated Evaluation of Gastrointestinal Symptoms)
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2016 · Synced Oct 23, 2026, 10:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

GI SPORE Colon Biosample Protocol

NCT02243267
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
sample collection
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function

NCT00094965
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Oxaliplatin (SR96669)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 30, 2009 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Gastrointestinal Manifestation of Fabry's Disease

NCT02798458
View directory record Official record
Conditions
Fabry's Disease
Interventions
Smartpill, Endoscopic Mucosal Resection
Device · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 23, 2026, 10:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool

NCT03082287
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Irritable Bowel Syndrome
Interventions
Fecal Calprotectin Level
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
22 Years and older
Enrollment
424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salem, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 23, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

NCT04858425
View directory record Official record
Conditions
Covid19
Interventions
Niclosamide, Placebo
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • DeLand, Florida • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 23, 2026, 10:03 AM EDT
Terminated Phase 2 Interventional Results available

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

NCT01886287
View directory record Official record
Conditions
Neuroendocrine Carcinoma
Interventions
Octreotide LAR
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Phase 2 Interventional

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

NCT01915602
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Programs To Support You During Chemotherapy

NCT02489422
View directory record Official record
Conditions
Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer, Stage IIC Colorectal Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IIIC Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Appendix Cancer, Stomach Cancer, Gallbladder Cancer, Liver Cancer, Small Intestine Cancer, Large Intestine Cancer, Anal Cancer, Biliary Tract Cancer, Gastrointestinal Stromal Cancer
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration, Yoga Skills Training, Attention Control, Actigraphy Assessment
Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 23, 2026, 10:03 AM EDT
Terminated Phase 1 Interventional Results available

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

NCT03449030
View directory record Official record
Conditions
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
Interventions
TAK-164, 89Zr-TAK-164
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Aurora, Colorado • Tampa, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 23, 2026, 10:03 AM EDT
Terminated No phase listed Observational

Incidence of Adverse Airway Events in High Risk Patients Undergoing Upper GI Endoscopy Under Anesthesia

NCT02011607
View directory record Official record
Conditions
SEDLine, Accoustic Respiratory Monitor RAD87, Adverse Events, Advanced Endoscopic Procedures
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Phase 4 Interventional

Improving Hepatitis C Treatment in Injection Drug Users

NCT00148031
View directory record Official record
Conditions
Hepatitis C, Liver Diseases, Drug Abuse, Alcoholism
Interventions
Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment, Off-site HCV evaluation and treatment
Drug · Behavioral
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 23, 2026, 10:03 AM EDT
Completed No phase listed Observational

Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients

NCT00502502
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional Results available

Hybrid APC Assisted EMR for Large Colon Polyps

NCT03390907
View directory record Official record
Conditions
Colon Polyp, Colon Adenoma, Colon Cancer
Interventions
Hybrid APC
Device
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gastrointestinal Tolerance Evaluation of an Infant Formula

NCT03307122
View directory record Official record
Conditions
Healthy, Full-term Infants Who Are Formula-fed
Interventions
Routine Infant Formula 1, Routine Infant Formula 2
Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
9 Days to 19 Days
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
8
States / cities
Pensacola, Florida • Louisville, Kentucky • Owensboro, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 23, 2026, 10:03 AM EDT
Active, not recruiting Phase 2 Interventional

NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer

NCT04005339
View directory record Official record
Conditions
Advanced Biliary Tract Cancer
Interventions
Nanoliposomal Irinotecan, Leucovorin, Fluorouracil
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Phase 1 Interventional

A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract

NCT01630798
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
GI heptapeptide
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Oct 23, 2026, 10:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

NCT03368963
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Stage IV Colorectal Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage III Colorectal Cancer, Stage III Gastric Cancer, Stage III Pancreatic Cancer, Unresectable Digestive System Adenocarcinoma, Unresectable Pancreatic Carcinoma
Interventions
Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 23, 2026, 10:03 AM EDT
Withdrawn Not applicable Interventional

Validation of Esophageal Variceal Grading: A Comparative Study of Upper Gastrointestinal (GI) Endoscopy and Capsule Endoscopy

NCT00475592
View directory record Official record
Conditions
Esophageal and Gastric Varices
Interventions
Esophageal Capsule Endoscopy, Upper Gastrointestinal Endoscopy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

NCT01055704
View directory record Official record
Conditions
Gastric Motility Disorder
Interventions
Methylnaltrexone only, Codeine only, Methylnaltrexone + codeine, Placebo + placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 23, 2026, 10:03 AM EDT
Completed Not applicable Interventional

Food as Medicine: An RCT to Study the Effect of Home Delivered, Medically Tailored Meals on Patients With Metastatic Cancer

NCT02887235
View directory record Official record
Conditions
Quality of Life
Interventions
Home Delivered, Medically Tailored Meals (HDTM)
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 23, 2026, 10:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-human Study of 7MW4911 in GI Cancer

NCT07216560
View directory record Official record
Conditions
GI Cancers
Interventions
7MW4911
Drug
Lead sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Port Saint Lucie, Florida • Boston, Massachusetts • Long Island City, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 23, 2026, 10:03 AM EDT
Completed No phase listed Observational

An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients

NCT00681759
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Brentwood, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2008 · Synced Oct 23, 2026, 10:03 AM EDT